Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai ZhenGe Completes $100 Million Round for Biologic CDMO Services

publication date: Jan 12, 2022

Shanghai ZhenGe Biotech completed a $100 million C Round to strengthen its biologic drug CDMO services. The company offers end-to-end services from concept to commercialization to help customers discover, develop and manufacture biologics. Founded in 2017, ZhenGe has worked with more than 100 biopharma and biotech customers, completing over 150 projects that range from cell line development projects to IND applications and clinical trial production. ZhenGe has expertise with monoclonal and bispecific antibodies, ADCs, fusion proteins and vaccines. The C Round was led by Goldman Sachs Asset Management and Sofina. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital